Stock Track | HUTCHMED Soars as UK Approves Cancer Drug Fruquintinib

Stock Track

2024-09-20

Shares of HUTCHMED (HCM), a leading biopharmaceutical company focused on oncology and immunology drugs, soared 7.58% on Thursday after the UK's healthcare regulator granted approval for its drug Fruquintinib to treat metastatic colorectal cancer in adult patients.

The Medicines and Healthcare products Regulatory Agency (MHRA) approval marks a significant milestone for HUTCHMED, allowing the company to market Fruquintinib in the UK for colorectal cancer treatment. Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3.

The regulatory greenlight bolsters HUTCHMED's oncology portfolio and is expected to drive revenue growth for the company. Analysts view the approval as a positive development, highlighting the drug's potential in addressing a significant unmet medical need in the treatment of metastatic colorectal cancer.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1151558670"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1151558670\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1151558670?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-20 20:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1151558670","market":"hk","top_or_hot":-1,"title":"Stock Track | HUTCHMED Soars as UK Approves Cancer Drug Fruquintinib","media":"Stock Track","content":"<html><body><p>Shares of HUTCHMED (HCM), a leading biopharmaceutical company focused on oncology and immunology drugs, soared 7.58% on Thursday after the UK's healthcare regulator granted approval for its drug Fruquintinib to treat metastatic colorectal cancer in adult patients.</p>\n<p>The Medicines and Healthcare products Regulatory Agency (MHRA) approval marks a significant milestone for HUTCHMED, allowing the company to market Fruquintinib in the UK for colorectal cancer treatment. Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3.</p>\n<p>The regulatory greenlight bolsters HUTCHMED's oncology portfolio and is expected to drive revenue growth for the company. Analysts view the approval as a positive development, highlighting the drug's potential in addressing a significant unmet medical need in the treatment of metastatic colorectal cancer.</p></body></html>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Stock Track | HUTCHMED Soars as UK Approves Cancer Drug Fruquintinib</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | HUTCHMED Soars as UK Approves Cancer Drug Fruquintinib\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-09-20 20:32</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Shares of HUTCHMED (HCM), a leading biopharmaceutical company focused on oncology and immunology drugs, soared 7.58% on Thursday after the UK's healthcare regulator granted approval for its drug Fruquintinib to treat metastatic colorectal cancer in adult patients.</p>\n<p>The Medicines and Healthcare products Regulatory Agency (MHRA) approval marks a significant milestone for HUTCHMED, allowing the company to market Fruquintinib in the UK for colorectal cancer treatment. Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3.</p>\n<p>The regulatory greenlight bolsters HUTCHMED's oncology portfolio and is expected to drive revenue growth for the company. Analysts view the approval as a positive development, highlighting the drug's potential in addressing a significant unmet medical need in the treatment of metastatic colorectal cancer.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00013","symbol_name":"和黄医药","start_time":0,"source_url":"","article_id":"1151558670","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1151558670","pubTimestamp":1726835540,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of HUTCHMED , a leading biopharmaceutical company focused on oncology and immunology drugs, soared 7.58% on Thursday after the UK's healthcare regulator granted approval for its drug Fruquintinib to treat metastatic colorectal cancer in adult patients.The Medicines and Healthcare products Regulatory Agency  approval marks a significant milestone for HUTCHMED, allowing the company to market Fruquintinib in the UK for colorectal cancer treatment. Fruquintinib is a highly selective and poten","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00013":"和黄医药"},"translate_title":"英国批准抗癌药物呋喹替尼，和黄医药股价飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00013":1},"content_text":"Shares of HUTCHMED (HCM), a leading biopharmaceutical company focused on oncology and immunology drugs, soared 7.58% on Thursday after the UK's healthcare regulator granted approval for its drug Fruquintinib to treat metastatic colorectal cancer in adult patients.\nThe Medicines and Healthcare products Regulatory Agency (MHRA) approval marks a significant milestone for HUTCHMED, allowing the company to market Fruquintinib in the UK for colorectal cancer treatment. Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3.\nThe regulatory greenlight bolsters HUTCHMED's oncology portfolio and is expected to drive revenue growth for the company. Analysts view the approval as a positive development, highlighting the drug's potential in addressing a significant unmet medical need in the treatment of metastatic colorectal cancer.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1}}}